论文信息 - Potential of FX06 to prevent disease progression in hospitalized non-intubated COVID-19 patients — the randomized, EU-wide, placebo-controlled, phase II study design of IXION - 字舞流文

Potential of FX06 to prevent disease progression in hospitalized non-intubated COVID-19 patients — the randomized, EU-wide, placebo-controlled, phase II study design of IXION

P. Meybohm | P. Kranke | C. V. D. van der Kallen | P. Couceiro | K. Zacharowski | S. Lindau | E. De Robertis | Neringa Vagulienė | D. Tomescu | A. Macas | C. Stephan | M. Vehreschild | T. Steiner | C. Stehouwer | O. Old | K. Lacombe | A. Foldenauer | A. Riera-Mestre | P. Cerdà | A. Iriarte | J. M. Mora-Luján | S. Dauth | T. Schlesinger | S. Hottenrott | P. Booms | Sebastian Zinn | A. V. van Asselt | M. van Hulst | T. Wolf | M. Popescu | P. Wülfroth | E. Kranke | Catarina Monteiro | D. Röder | J. Kloka | Benjamin Friedrichson | Magdalena Sitter | B. Schmid | T. Chiarabini | A. Bulczak-Schadendorf | Francisco Maio Matos | Vilma Traskaite Juskeviciene | Oliver Markus Lea Patrick Simone Sebastian Isabel Timo Ch Old Ketomaeki Grebe Booms Lindau Zinn Maus | Markus Ketomaeki | Lea Grebe | Isabel Maushagen | Cathy Weynants | Sylvia Daamen | T. Haas | Philipp Schlesinger | David Valeri | R. Iglesias | Jolanta Litviniene | Kristina Balnė | Inês A. Ferreira | P. Soares | Sofia Beirão | Y. Aad | F. Matos | Sebastian Hottenrott | P. Schlesinger

[1] D. Skovronsky,et al. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. , 2021, JAMA.

[2] Shuilin Jin,et al. The scRNA-seq Expression Profiling of the Receptor ACE2 and the Cellular Protease TMPRSS2 Reveals Human Organs Susceptible to SARS-CoV-2 Infection , 2021, International journal of environmental research and public health.

[3] C. Silvestri,et al. Treatment for COVID-19: An overview , 2020, European Journal of Pharmacology.

[4] P. Meybohm,et al. Fibrin-derived peptide Bβ15-42 (FX06) as salvage treatment in critically ill patients with COVID-19-associated acute respiratory distress syndrome , 2020, Critical Care.

[5] O. Tsang,et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. , 2020, JAMA.

[6] Mike Clarke,et al. A minimal common outcome measure set for COVID-19 clinical research , 2020, The Lancet Infectious Diseases.

[7] Amit N. Patel,et al. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 , 2020, The New England journal of medicine.

[8] Holger Moch,et al. Endothelial cell infection and endotheliitis in COVID-19 , 2020, The Lancet.

[9] Martin Stahl,et al. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2 , 2020, Cell.

[10] T. Walther,et al. Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts , 2020, European heart journal.

[11] Manish Bansal,et al. Cardiovascular disease and COVID-19 , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[12] K. Yuen,et al. Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[13] Zunyou Wu,et al. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[14] E. Dong,et al. An interactive web-based dashboard to track COVID-19 in real time , 2020, The Lancet Infectious Diseases.

[15] Yan Zhao,et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[16] Jing Zhao,et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.

[17] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[18] Zhènglì Shí,et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody , 2020, bioRxiv.

[19] B. Scheller,et al. The Fibrin Cleavage Product Bβ15-42 Channels Endothelial and Tubular Regeneration in the Post-acute Course During Murine Renal Ischemia Reperfusion Injury , 2018, Front. Pharmacol..

[20] P. Meybohm,et al. The Fibrin-Derived Peptide B&bgr;15–42 (FX06) Ameliorates Vascular Leakage and Improves Survival and Neurocognitive Recovery: Implications From Two Animal Models of Cardiopulmonary Resuscitation* , 2016, Critical care medicine.

[21] T. Vogl,et al. Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care , 2015, The Lancet.

[22] David Moher,et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials , 2013, BMJ.

[23] P. Friedl,et al. The Fibrin-Derived Peptide B&bgr;15-42 Significantly Attenuates Ischemia-Reperfusion Injury in a Cardiac Transplant Model , 2010, Transplantation.

[24] P. Friedl,et al. Peptide Bβ15-42 Preserves Endothelial Barrier Function in Shock , 2009, PloS one.

[25] D. Atar,et al. Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial. , 2009, Journal of the American College of Cardiology.

[26] B. Vollmar,et al. A double blind, single centre, sub-chronic reperfusion trial evaluating FX06 following haemorrhagic shock in pigs. , 2009, Resuscitation.

[27] K. Wolff,et al. The fibrin-derived peptide Bβ15–42 protects the myocardium against ischemia-reperfusion injury , 2005, Nature Medicine.

[28] P. Zacharowski,et al. The fibrin-derived peptide Bbeta~1~5~-~4~2 protects the myocardium against ischemia-reperfusion injury , 2005 .

[29] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..